Equities

Mayinglong Pharmaceutical Group Co Ltd

600993:SHH

Mayinglong Pharmaceutical Group Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)22.09
  • Today's Change0.19 / 0.87%
  • Shares traded5.47m
  • 1 Year change-3.07%
  • Beta1.3420
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2,9143,1682,523
Total Receivables, Net393447293
Total Inventory273336314
Prepaid expenses546869
Other current assets, total138206162
Total current assets3,7724,2263,361
Property, plant & equipment, net656515445
Goodwill, net252525
Intangibles, net1628067
Long term investments153151177
Note receivable - long term------
Other long term assets1.568.141.92
Total assets4,8305,0894,127
LIABILITIES
Accounts payable210151127
Accrued expenses11330178
Notes payable/short-term debt131221128
Current portion long-term debt/capital leases332821
Other current liabilities, total194427211
Total current liabilities681858665
Total long term debt19452273
Total debt358771222
Deferred income tax29362.51
Minority interest132121143
Other liabilities, total565672
Total liabilities1,0921,593956
SHAREHOLDERS EQUITY
Common stock431431431
Additional paid-in capital52101105
Retained earnings (accumulated deficit)3,2532,9612,634
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total2.662.461.28
Total equity3,7383,4953,171
Total liabilities & shareholders' equity4,8305,0894,127
Total common shares outstanding431431431
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.